, Volume 103, Issue 3, pp 797-801
Date: 13 Nov 2010

mTORC1 activation in childhood ependymoma and response to sirolimus

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient’s tumor.